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, Abstract—Background: Legalization of medical and
recreational cannabis is a major contributor to pediatric
cannabis exposures. The trends and magnitude of pediatric
cannabis exposures in Michigan after medical cannabis
legalization in 2008 have not been assessed. Objective: To
describe the temporal trends of pediatric cannabis exposures reported to the Michigan Poison Center (MiPC) after
medical cannabis was legalized in 2008 and 1 year after
legalization of recreational cannabis in 2018. Methods:
Retrospective electronic chart review of pediatric (<18 years
old) single-substance cannabis exposures reported to the
MiPC from January 1, 2008 to December 31, 2019. Routes
of cannabis exposure were reported as ingestion, inhalation,
and unknown. Types of ingested cannabis products were
also documented. Results: Between 2008 and 2019, 426 pediatric cannabis single exposures were reported. The median
patient age was 6.0 years (interquartile range 2–15 years).
Age distribution was bimodal. A total of 327 (76.8%) exposures were from cannabis ingestion, 79 (18.5%) from inhalation, 2 (0.5%) from both ingestion and inhalation, and 18
(4.2%) from unknown route. The doubling time for number

of cases was 2.1 years, and the total number of annual reported cases increased after 2016. Teenagers (13–17 years)
had the highest number of inhalational exposures, whereas
young children (0–5 years) had the highest number of ingestions. Conclusion: Single-substance pediatric cannabis exposures reported to the Michigan Poison Center increased
after medical cannabis was legalized in 2008 through recreational legalization in 2018. Ó 2021 Elsevier Inc. All rights
reserved.
, Keywords—pediatrics; cannabis; marijuana; toxicology

INTRODUCTION
Cannabis, after alcohol, is the second most commonly
used psychotropic substance in the United States (1). A
2018 national survey showed that 34.8% of young adults
age 18 to 25 years and 12.5% of children age 12–17 had
used marijuana in the past year (1). In 2017, 36% of U.S.
students in grades 9–12 used marijuana, and the rate for
students in Michigan was slightly higher at 41% (2).
Although it is currently unknown whether adolescent
use of marijuana will rise due to the increasing nationwide trend in marijuana legalization, there is concern
that legalization provides greater opportunity for youth
marijuana acquisition and subsequent toxic exposures.

A preliminary version of these results was presented as an abstract (‘‘Trends in Marijuana Exposures Reported to Michigan
Poison Center from 2014 to 2019’’) at the Annual Scientific
Meeting hosted by the American College of Medical Toxicology, virtually, in March 2020 (New York, NY).
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At the federal level, cannabis remains a schedule I
drug, defined by the Drug Enforcement Administration
as a substance ‘‘with no currently accepted medical use
and a high potential for abuse’’ (3). At the state level,
adult use of cannabis is currently legal in 11 states,
including our state of Michigan, with anticipated additions of four more states after voter approval occurred
in the November 2020 elections (Arizona, Montana,
New Jersey, and South Dakota) (4).
A consequence of increased legalization and subsequent availability of cannabis products is a predictable
parallel increase in unintentional pediatric exposures. A
retrospective review of national poison center data that
compared state trends in unintentional pediatric cannabis
exposures with respect to state cannabis legislation status
found that the rate of pediatric exposure increased over a
7-year period (2005–2011) in states that had passed
cannabis legislation (5). Since then, studies in states
where marijuana was legalized or decriminalized have
continued to show a concomitant rise in pediatric
cannabis exposures and increases in emergency department visits or hospitalizations (6–8). For example, a
report that combined data from Rocky Mountain Poison
and Drug Center and Children’s Hospital of Colorado
found that calls to the state’s poison control center for
unintentional pediatric cannabis exposures between
2009
and
2015—when
medical
dispensaries
proliferated and recreational use was legalized—
increased 34% annually, significantly greater than the
19% increase in cannabis-related calls received by poison
control centers in the rest of the United States (9). A
further analysis of billing codes from hospitalizations in
Colorado related to cannabis exposure reported significant increases in patients aged 0–8 and 9–17 years after
liberalization of medical cannabis laws in 2010, and an
even further increase in exposure for these ages after
enactment of legalized recreational use in 2014 (10).
This suggests that liberalization of cannabis laws is
temporally related to increases in childhood cannabis exposures (11). Although studies have shown that national
surveys of adolescent cannabis use have remained stable,
encounters with health care facilities have increased (12–
14). Some states, such as Colorado, have passed
legislation focused on preventive measures, such as
child-proof packaging, opaque packaging, and limited
marketing, which thus far, have not been shown to be
effective at decreasing health care facility visits (15).
Medical cannabis became legal in Michigan in 2008,
and recreational cannabis became legal in 2018. As of
December 1, 2019, recreational cannabis products were
available for purchase. This manuscript reports the trend
in unintentional pediatric (<18 years old) singlesubstance cannabis exposures at risk of toxicity reported
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to the Michigan Poison Center with respect to the progression of laws pertaining to the changes in legal status
of cannabis from 2008 to 2019.
METHODS
We conducted a retrospective review of all singlesubstance cannabis cases reported to the Michigan Poison Center (MiPC) from 2008 to 2019. Michigan has a
population of approximately 10 million people covered
by one poison center. The MiPC is staffed by nurses,
pharmacists, and physicians (Poison Information Providers [PIPs] and Certified Specialists in Poison Information [CSPIs]) who take telephone calls from the
public and health care providers. Calls originating
from within Michigan or telephones with area codes
from Michigan are routed to the MiPC call center. Human poisoning advice is provided free of charge 24 h a
day, 365 days per year. The MiPC logs over 100,000
incoming and outgoing calls per year. CSPIs and
PIPs create a chart for every exposure reported, and
clinical and demographic data are entered into a secure
electronic toxicology database. The MiPC changed databases in August of 2019 from ToxiCALLÒ (Computer Automation Systems Inc., Aurora, CO) to
ToxSentryÔ (Jacksonville, FL) (ToxiCALL 1999–8/
2019 and ToxSentry 8/2019–present). This study was
approved by the Detroit Medical Center and Wayne
State University Institutional Review Boards.
To identify all cases of pediatric cannabis exposure,
we queried both databases: ToxiCALL (January 1,
2008–July 31, 2019) and ToxSentryÔ (August 1, 2019–
December 31, 2019). Investigators searched using the
following key words: ‘‘marijuana,’’ ‘‘marihuana,’’
‘‘THC,’’ ‘‘cannabis,’’ and ‘‘cannabinoids.’’ Each chart
generated by keyword searches was reviewed by authors
(DD and AK) to confirm that they met the following inclusion criteria: 1) patients were exposed only to a
cannabis product; 2) patients were intoxicated with
symptoms consistent with cannabis exposure or were at
high risk of developing symptoms (judged by the MiPC
specialists), and 3) patients were age 17 years and
younger. We excluded cases that were deemed to be of
unlikely significance, such as tastes, licks, or secondhand
smoke exposures. We chose to exclude cases that
involved multiple substances because those cases may
have represented toxicity that was not due to cannabis
(e.g., ethanol, alprazolam), which would potentially
confound interpretation of cannabis intoxication.
Furthermore, it is important to note that charts are often
coded for cannabis if a urine drug test is positive for tetrahydrocannabinol (THC), and this would decrease the
specificity for cannabis intoxication/toxicity. Finally,

Downloaded for Anonymous User (n/a) at Henry Ford Hospital / Henry Ford Health System (CS North America) from ClinicalKey.com by Elsevier on March 11, 2021.
For personal use only. No other uses without permission. Copyright ©2021. Elsevier Inc. All rights reserved.

Pediatric Cannabis Exposure Trends After Medical Marijuana Legalization

unintentional intoxication in young children was our
main outcome of interest. We excluded cases of cannabinoid hyperemesis, calls regarding chronic usage, and information calls.
We collected the following data: unique case number,
age, year of exposure, and type of exposure. Types of exposures were categorized as: 1) ingestion; 2) inhalation;
and 3) unknown/not otherwise specified. Ingestions
were further subcategorized into ingestion of 1) ‘‘edibles’’ and 2) nonfoodstuffs or ingestion detail not documented. ‘‘Edibles’’ were defined as foodstuff created to
be ingested, such as cookies, candies, gummies, chocolates, and brownies.
A linear regression line was fit to log10 cases over
time. Given the exponential nature of the data, the estimated doubling time was calculated overall and for edible
ingestion only, using the tangent line at time 0 on these
semi-log graphs, where delta(t) = log(2)/slope. All analyses were performed using SAS 9.4 (SAS Institute Inc,
Cary, NC). We stratified the analysis into three age
groups: 0–5 years, 6–12 years, and 13–17 years. We
then calculated the median and interquartile range
(IQR) of age for all exposures and the subcategory of
edible ingestions.
RESULTS
Between 2008 and 2019, a total of 1392 cannabis exposures in children younger than 18 years old were reported
to the MiPC. We excluded 743 cases of co-exposures and
220 cases that were judged to be insignificant (licks,
tastes, secondhand smoke) or were lost to follow-up, resulting in 426 cases of single-substance pediatric
cannabis exposures. Total exposures reported to the
MiPC ranged from 47,908 in 2008 to 54,717 in 2019,
with a peak in 2010 at 72,792 reported exposures
(Table 1). Despite the inconsistent trend in exposure vol-

3

ume reported to the MiPC over the study time period, the
percentage of isolated pediatric cannabis exposures has
increased over the study time period (0.01% to 0.24%).
The median age of children who had isolated cannabis
exposures was 6.0 years (IQR 2–15), with 209 cases for
children age 0–5 years (49.1%), 45 cases for children
age 6–12 years (10.6%), and 172 cases for children age
13–17 years (40.3%). The cases exhibited a bimodal
age distribution (Figure 1), with the fewest cases reported
for the age range of 6–12 years and the most cases reported for children 0–5 years and 13–17 years.
From 2008 to 2019, the number of isolated pediatric
cannabis cases reported to MiPC consistently increased
each year, following an exponential pattern, with a
doubling time of 2.1 years (Figure 2). Ingestion was the
most common route of exposure (327 [76.8%]), followed
by inhalation (79 [8.5%]), unknown (18 [4.2%]), and
combination ingestion and inhalation (2 [0.5%])
(Figure 3). From 2008 until 2016, the total number of
cases reported per year was consistently below 30. In
2016, the number of total annual reported cases began
to rise and was driven by edible cannabis items
(Figure 2): the number of annual reports for ingestions
rose between 2016 and 2019, whereas the number of
inhalational exposures remained somewhat steady
throughout the entire study period (mean 6.6 inhalations
per year). One exception of 21 inhalational exposures was
reported in 2019.
The ingestion data (not including the two ingestion and
inhalation events) were further subdivided into ‘‘edible’’
vs. ‘‘nonedible’’ sources (see Methods). Of the 327 ingestion events recorded, 227 (69.4%) were from edible products, and 100 (30.5%) were from nonedible sources. The
median age of children exposed to edible cannabis products was 5 years (IQR 3–14), and the distribution of age
of exposure to edible cannabis was also bimodal
(Figure 1). The doubling time between 2008 and 2019

Table 1. Site of Origin of Call to MiPC by Year
Origin of Call

MML

RML
Total

Year

Total MiPC Exposures

Total Pediatric Isolated Cannabis
Exposures

2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019

47,908
61,786
72,492
69,540
67,284
61,727
57,919
60,162
61,211
58,232
55,771
54,717
728,749

7
4
12
14
29
15
23
21
33
49
86
133
426

HCF

Home

1
2
9
9
18
11
20
16
24
42
66
96
314

6
2
3
5
11
4
3
5
9
7
20
37
112

MiPC = Michigan Poison Center; HCF = health care facility; MML = medical marijuana legalization; RML = recreational marijuana legalization.
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Figure 1. Bimodal distribution of pediatric cannabis exposures by age (2008–2019). MiPC = Michigan Poison Center.

for reported edible cannabis exposures among pediatric
patients was 2.3 years, slightly longer than for overall exposures, again fitting an exponential pattern (Figure 2).
Inhalational exposures were highest in teenagers (13–
17 years), whereas ingestions from both edible and
nonedible sources were highest in young children (0–
5 years) (Figure 3). Most calls originated from a health
care facility (314 [74%]), and the remaining calls originated from home or school (112 [26%]) (Table 1).

DISCUSSION
Analysis of the MiPC pediatric cannabis single-agent
exposure data, the largest case series to our knowledge
to date, revealed an overall increase in annual pediatric
exposures of cannabis in Michigan in the years from medical cannabis legalization in 2008 through recreational
cannabis legalization in 2018. A bimodal distribution in
age groups showed that children ages 0–5 and teenagers

Figure 2. Pediatric single-substance cannabis exposures reported to Michigan Poison Center (MiPC) by exposure type (A) and by
age range (B) from 2008-2019.
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Figure 3. Cannabis exposures by age group and route (2008-2019). Breakdown of main exposure routes per age group showing
predominant route of exposure for young children 0–5 years old was ingestions, whereas teenagers 13–17 years old had the highest number of reported inhalation exposures. Number of nonedible ingestions for age 6–12 was eight.

13–17 years were most affected, and that the trend was
driven by ingested edible cannabis products. We hypothesize that this distribution is predictable and conforms to
normal human development: oral exploratory behaviors
in very young children; affinity for cookies and candy
in slightly older children; and autonomy, peer pressure,
and experimental behavior in teens.
This study was not designed to identify the cause of
the rapid increase in poison center calls of cannabis exposure in Michigan. However, exposure to edibles was the
main driver. This may be due to one or a combination
of factors: 1) edible products are increasingly available,
2) edibles continue to mimic mainstream noncannabis
sweets and candy and are not sold or distributed in
child-resistant packaging (despite state-mandated packaging restrictions to the contrary), 3) residents are making
homemade edible products that are not subject to state
regulations, 4) cannabis has increased in potency, and
5) reporting of toxic exposures has increased (16).
Acute toxicity in teens is problematic; teens are having
cannabis-related health events significant enough to be
evaluated in a health care setting at an increasing rate,
occurring at a time of rapid brain development and differentiation. Both ingestion and inhalational exposures can
lead to anxiety, panic attacks, psychosis, altered mental
status, dangerous behaviors, and a number of other health
and psychiatric effects. Edible products are more likely to
result in accidental overdose than inhaled products due to
slow onset of action of THC after consumption and subsequent ‘‘dose-stacking’’ effects. Cannabis potency

(percent concentration of THC by volume) and use of
concentrated products (e.g., ‘‘dab,’’ ‘‘wax,’’ ‘‘honey’’)
likely play a role as well.
Cannabis has become a major industry in states
where its recreational use is now legal. For example,
in Colorado, legal cannabis generated over $300 million
in tax revenue for the state in 2019 alone, and this has
been increasing yearly since the state began reporting
on the subject (17). As of the writing of this manuscript,
medical cannabis is available within Michigan at 213
provisioning centers, 61 recreational cannabis retailers,
and with 111 recreational cannabis licenses granted
(18). Michigan sold nearly $32 million worth of recreational marijuana in its first 3 months of operation
(December 2019 to February 2020), with March and
April 2020 demonstrating consistent upward trends of
$21.9 and $27.8 million, respectively, generating $1.2–
1.55 million in monthly tax revenue (18,19). This industry will likely continue to be a significant portion of
Michigan’s economy going forward, and its legal status
is unlikely to change. This upward sales trend represents
increased availability and risk for unintentional pediatric
exposure.
Many states have adopted rules and regulations that
comport with the 2015 American Academy of Pediatrics
policy statement on cannabis to forbid direct advertising
to children and to require packaging practices to prevent
unintentional pediatric use and poisoning (20). Indeed, as
of April 2020, 15 states (AL, CA, CO, CT, HI, IL, MA,
MD, ME, MN, MT, NM, NV, NY, WA) have childproof
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packaging requirements, and 13 (AL, AZ, CO, CA, FL,
MA, MD, MN, NM, NV, NY, OR, WA) have specific labeling instructions to keep products away from children
(3,21). In Michigan, the Marijuana Regulatory Agency
within the Department of Licensing and Regulatory Affairs was created to establish rules for edible cannabis.
These rules state: 1) ‘‘No edible marihuana product package can be in a shape or labeled in a manner that would
appeal to minors aged 17 years or younger,’’ 2) ‘‘No
edible marihuana product can be easily confused with
commercially sold candy,’’ and 3) ‘‘An edible marihuana
product must be in opaque, child-resistant packages or
containers that meet the effectiveness specifications outlined in 16 CFR 1700.15’’ (18). However, even in states
that have enacted such regulations, increases in unintentional exposures and health care facility visits still have
occurred at substantial rates (7,15). It remains unclear
what impact packaging rules and legislation will have
on reported pediatric exposures, and further study may
reveal differences in younger vs. adolescent pediatric
populations.
Going forward, preemptive and planned regulations to
ensure proper labeling and packaging is logical and recommended by the American Academy of Pediatrics and
these authors, and the effectiveness of preventive measures should continue to be evaluated and reported. Preventing teenage exposures may require tactics other
than regulation of labeling or child-proof packaging,
such as peer-to-peer health educational programs and
campaigns. Future research should examine the influence
of specific policies to determine which strategies are most
effective for preventing pediatric exposures and to
develop evidence-based recommendations. Prospective
enumeration of product type, manufacturer (including
homemade), potency, and distributor is also suggested
to identify responsible parties.
States that are considering medical or recreational
cannabis legalization should be aware of the trends
demonstrated in Michigan and other states. Poison centers and acute care facilities located in those states should
expect to see a continued increase in pediatric cannabis
exposures, regardless of associated regulatory safeguards.
Limitations
Limitations to Poison Center data have been extensively
reviewed (22). As with other poison center-based studies,
our results are subject to selection and reporting bias.
Specifically, disease severity may be overestimated
because severe cases are more likely to be reported to
the poison center and may be provider and institution
dependent. Additionally, poison center charts are of variable quality. Details of ingestion exposure can some-
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times be limited, and therefore we may not have
captured all of the edible exposures.
We chose to exclude all reported exposures that reported any type of co-ingestants. Although this choice
limits the number of cases, it also removes confounding
ingestions and toxicities. We limited our search terms
to ‘‘cannabinoid, cannabis, THC, marijuana, and marihuana’’ because these are the terms most often used by
poison center staff to code exposure. Other terms may
have been used, and we assume these terms to be infrequently used and their exclusion unlikely to affect results.
CONCLUSION
Cannabis exposures reported to the MiPC consistently
increased among pediatric patients in the period after
medical cannabis legalization (2008) and leading up to
recreational cannabis legalization (2019) in the state of
Michigan. The mitigating effects of aggressive education
campaigns, product labeling, and childproof/resistant
packaging are unknown. Future research is needed to
evaluate the effects of cannabis regulations and public
health campaigns on unintentional pediatric cannabis exposures to inform the development of prevention and
mitigation strategies.

REFERENCES
1. Substance Abuse and Mental Health Services Administration
(SAMHSA). Results from the 2018 National Survey on Drug Use
and Health. Available at: https://www.samhsa.gov/data/report/
2018-nsduh-detailed-tables. Accessed April 15, 2020.
2. Centers for Disease Control and Prevention (CDC). 1991-2017
High School Youth Risk Behavior Survey. Available at: http://
nccd.cdc.gov/YouthOnline/App/Default.aspx. Accessed April 15,
2020.
3. U.S. Drug Enforcement Agency. Drug scheduling. Available at:
https://www.dea.gov/drug-scheduling. Accessed May 5, 2020.
4. Ballotpedia. 2020 marijuana legalization and marijuana-related ballot measures. Available at: https://ballotpedia.org/2020_marijuana_
legalization_and_marijuana-related_ballot_measures.
Accessed
November 30, 2020.
5. Wang GS, Roosevelt G, Le Lait MC, et al. Association of unintentional pediatric exposures with decriminalization of marijuana in
the United States. Ann Emerg Med 2014;63:684–9.
6. Drug Abuse Warning Network (DAWN), Substance Abuse and
Mental Health Services Administration (SAMHSA). Highlights of
the 2011 DAWN findings on drug-related emergency department
visits. Available at: www.samhsa.gov/data/sites/default/files/
DAWN127/DAWN127/sr127-DAWN-highlights.pdf.
Accessed
April 17, 2020.
7. Whitehill JM, Harrington C, Lang CJ, Chary M, Bhutta WA,
Burns MM. Incidence of pediatric cannabis exposure among children and teenagers aged 0 to 19 years before and after medical marijuana legalization in Massachusetts. JAMA Netw Open 2019;2:
e199456.
8. Thomas AA, Von Derau K, Bradford MC, Moser E, Garrard A,
Mazor S. Unintentional pediatric marijuana exposures prior to
and after legalization and commercial availability of recreational
marijuana in Washington State. J Emerg Med 2019;56:398–404.

Downloaded for Anonymous User (n/a) at Henry Ford Hospital / Henry Ford Health System (CS North America) from ClinicalKey.com by Elsevier on March 11, 2021.
For personal use only. No other uses without permission. Copyright ©2021. Elsevier Inc. All rights reserved.

Pediatric Cannabis Exposure Trends After Medical Marijuana Legalization
9. Wang GS, Le Lait MC, Deakyne SJ, Bronstein AC, Bajaj L,
Roosevelt G. Unintentional pediatric exposures to marijuana in Colorado, 2009–2015. JAMA Pediatr 2016;170:e160971.
10. Wang GS, Hall K, Vigil D, Banerji S, Monte A, VanDyke M. Marijuana and acute health care contacts in Colorado. Prev Med 2017;
104:24–30.
11. Hasin DS. US epidemiology of cannabis use and associated problems. Neuropsychopharmacology 2018;43:195–212.
12. Johnson J, Hodgkin D, Harris SK. The design of medical marijuana
laws and adolescent use and heavy use of marijuana: analysis of 45
states from 1991 to 2011. Drug Alcohol Depend 2017;170:1–8.
13. Hasin DS, Wall M, Keyes KM, et al. Medical marijuana laws and adolescent marijuana use in the USA from 1991 to 2014: results from annual,
repeated cross-sectional surveys. Lancet Psychiatry 2015;2:601–8.
14. Wang GS, Davies SD, Halmo LS, Sass A, Mistry RD. Impact of
marijuana legalization in Colorado on adolescent emergency and
urgent care visits. J Adolesc Health 2018;63:239–41.
15. Wang GS, Hoyte C, Roosevelt G, Heard K. The continued impact of
marijuana legalization on unintentional pediatric exposures in Colorado. Clin Pediatr (Phila) 2019;58:114–6.
16. Marijuana Regulatory Agency. Adult-use marihuana establishments: Emergency Rules. State of Michigan Department of

17.
18.

19.

20.

21.
22.

7

Licensing and Regulatory Affairs. Available at: https://www.
michigan.gov/documents/lara/Adult_Use_Marihuana_Establishments
_659804_7.pdf. Accessed April 15, 2020.
Colorado Department of Revenue. Marijuana tax data. Available at:
https://www.colorado.gov/pacific/revenue/colorado-marijuana-taxdata. Accessed June 15, 2020.
Marijuana Regulatory Agency. Monthly report: March 2020. State
of Michigan Department of Licensing and Regulatory Affairs.
Available at: https://www.michigan.gov/documents/lara/Monthly_
Report_March_2020_687859_7.pdf. Accessed June 9, 2020.
Marijuana Regulatory Agency. Monthly report: April 2020. State of
Michigan Department of Licensing and Regulatory Affairs. Available at: https://www.michigan.gov/documents/mra/Monthly_
Report_-_April_2020_690574_7.pdf. Accessed June 9, 2020.
Ammerman S, Ryan S, Adelman WP, Committee on Substance
Abuse, the Committee on Adolescence. The impact of marijuana
policies on youth: clinical, research, and legal update. Pediatrics
2015;135:e769–85.
NORML. State laws. Available at: https://norml.org/states. Accessed April 17, 2020.
Hoffman RS. Understanding the limitations of retrospective analyses of poison center data. Clin Toxicol (Phila) 2007;45:943–5.

Downloaded for Anonymous User (n/a) at Henry Ford Hospital / Henry Ford Health System (CS North America) from ClinicalKey.com by Elsevier on March 11, 2021.
For personal use only. No other uses without permission. Copyright ©2021. Elsevier Inc. All rights reserved.

8

D. Dean et al.

ARTICLE SUMMARY
1. Why is this topic important?
As the legislative landscape of marijuana use is changing, focusing on decriminalization, legalization, and overall movements of liberalization of cannabis use, it is
important to discuss potential unintended consequences
of these changes, especially among our vulnerable pediatric population. Pediatric cannabis exposures, both intentional and unintentional, have the potential to cause
negative unintended health consequences—including intoxications, hospital visits, and intensive care unit stays
among the most dramatic. Monitoring exposure cases in
the context of the legislative changes at the level of one
state has the potential to guide future legislations to aid
in the risk/benefit discussions that can be used by other
states considering future changes.
2. What does this study attempt to show?
We propose that the increasing liberalization of the attitudes around adult cannabis use, reflected by state legislative actions, has unintended consequences leading to
increases in (both intentional and unintentional) pediatric
cannabis exposures.
3. What are the key findings?
We demonstrate a large increase in exposures across
pediatric age groups spanning the time between medical
marijuana legalization in 2008 and legalization of recreational marijuana in 2018. All age groups were affected,
and a dramatic increase in edible exposure was noted.
4. How is patient care impacted?
Health care providers should be aware of the increased
numbers of exposures to cannabis in the pediatric population, as it is important to include this intoxication in the
differential of altered pediatric patients.
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